Galimedix Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $1M

  • Investors
  • 4

Galimedix Therapeutics General Information

Description

Developer of small molecule therapeutics designed to address the underlying causes of neurodegenerative diseases by blocking key steps in the neurodegenerative process. The company offers small-molecule compounds with a selective mechanism of action that blocks a key step in neurodegeneration while preserving normal neuronal function, enabling medical practitioners managing neurodegenerative and eye-related disorders to slow or halt disease progression and improve visual function across conditions such as dry age-related macular degeneration, glaucoma, and Alzheimer's disease.

Contact Information

Website
www.galimedix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3704 Calvend Lane
  • Kensington, MD 20895
  • United States
+1 (301)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 3704 Calvend Lane
  • Kensington, MD 20895
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Galimedix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 31-Dec-2020 $1M Completed Clinical Trials - Phase 2
2. Seed Round 30-Jun-2019 Completed Clinical Trials - Phase 2
1. University Spin-Out 06-Sep-2018 Completed Startup
To view Galimedix Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Galimedix Therapeutics Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Galimedix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026229894-A1 Treatment of cardiovascular and related disease Pending 29-Apr-2025
WO-2026018131-A1 Ocular compositions Pending 14-Jul-2024
WO-2025163607-A1 Use of lecanemab in ophthalmological conditions Pending 04-Feb-2024
EP-4518859-A1 Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects Pending 04-May-2022
EP-4518859-A4 Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects Pending 04-May-2022 A61K31/4045
To view Galimedix Therapeutics’s complete patent history, request access »

Galimedix Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Galimedix Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
InFocus Capital Partners Venture Capital Minority
Merz Pharma Corporation Minority
Rimonci Capital Venture Capital Minority
Ramot at Tel Aviv University University
To view Galimedix Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Galimedix Therapeutics FAQs

  • When was Galimedix Therapeutics founded?

    Galimedix Therapeutics was founded in 2018.

  • Where is Galimedix Therapeutics headquartered?

    Galimedix Therapeutics is headquartered in Kensington, MD.

  • What is the size of Galimedix Therapeutics?

    Galimedix Therapeutics has 15 total employees.

  • What industry is Galimedix Therapeutics in?

    Galimedix Therapeutics’s primary industry is Drug Discovery.

  • Is Galimedix Therapeutics a private or public company?

    Galimedix Therapeutics is a Private company.

  • What is Galimedix Therapeutics’s current revenue?

    The current revenue for Galimedix Therapeutics is .

  • How much funding has Galimedix Therapeutics raised over time?

    Galimedix Therapeutics has raised $3M.

  • Who are Galimedix Therapeutics’s investors?

    InFocus Capital Partners, Merz Pharma, Rimonci Capital, and Ramot at Tel Aviv University have invested in Galimedix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process